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ABSTRACT: Childhood tuberculosis (TB) is a preventable and curable infectious disease that
remains overlooked by public health authorities, health policy makers and TB control
programmes. Childhood TB contributes significantly to the burden of disease and represents
the failure to control transmission in the community. Furthermore, the pool of infected children
constitutes a reservoir of infection for the future burden of TB. It is time to prioritise childhood TB,
advocate for addressing the challenges and grasp the opportunities in its prevention and control.
Herein, we propose a scientifically informed advocacy agenda developed at the International
Childhood TB meeting held in Stockholm, Sweden, from March 17 to 18, 2011, which calls for a
renewed effort to improve the situation for children affected by Mycobacterium tuberculosis
exposure, infection or disease. The challenges and needs in childhood TB are universal and apply
to all settings and must be addressed more effectively by all stakeholders.
KEYWORDS: Control, infectious disease, Mycobacterium tuberculosis, public health
I
t is estimated that of the nine million tubercu-
losis (TB) cases occurring every year world-
wide, one million occur among children [1].
However, estimates of the burden of childhood TB
are uncertain, and under-reporting and under-
estimation of the global numbers are likely. In most
settings, children with TB continue to be given low
priority by National TB control Programmes (NTP)
because they are less likely to transmit disease. Pro-
vision of more accurate data by national surveil-
lance programmes is essential for improved global
TB-burden estimates among children. Childhood
TB has been largely absent from the global public
health agenda despite being a major contributor to
childhood morbidity and mortality particularly in
high TB-burden settings and advocacy and scien-
tific progress are still insufficient. Guidelines for
childhood TB management have been deve-
loped and are already adopted by many countries.
However, a wide policy/practice gap remains that
needs to be addressed. Advocacy for the imple-
mentation and monitoring of these policies is,
therefore, critical.
THE INTERNATIONAL CHILDHOOD TB
MEETING
The first International Childhood TB meeting
dedicated to advocacy was organised by the Stop
TB Partnership and the European Centre for Di-
sease Prevention and Control and was held in
Stockholm, Sweden, from March 17 to 18, 2011.
The meeting highlighted the challenges and suc-
cesses in research and control of childhood TB and
identified key areas where advocacy and targeted
engagement with stakeholders is needed. The aim
was to identify the advocacy priorities for child-
hood TB and to bring forward the voice of the
children. The meeting was attended by over 110
participants representing the global TB control com-
munity, paediatricians, researchers, former patients,
civil society, global health activists, advocacy ex-
perts, donors, governmental agencies and indus-
try. This broad audience engaged in discussions and
shared views on how best to raise the awareness of
childhood TB.
CHALLENGES AND NEEDS IN RESEARCH
AND DEVELOPMENT FOR CHILDHOOD TB
Research needs to address the unique aspects of
childhood TB and needs to function as an essential
vehicle towards the elimination of TB. Children
are more susceptible than adults to progress from
Mycobacterium tuberculosis exposure to infection
and to disease, which implies that the immune
mechanisms mediating protection might be dif-
ferent compared to those in adults. To increase our
AFFILIATIONS
For author affiliations, please refer to
the Acknowledgements section.
CORRESPONDENCE
A. Sandgren
European Centre for Disease
Prevention and Control
Tomtebodavagen 11a
Stockholm
17183
Sweden
E-mail: andreas.sandgren@
ecdc.europa.eu
Received:
Oct 27 2011
Accepted after revision:
Dec 13 2011
First published online:
Feb 15 2012
European Respiratory Journal
Print ISSN 0903-1936
Online ISSN 1399-3003
294 VOLUME 40 NUMBER 2 EUROPEAN RESPIRATORY JOURNAL
Eur Respir J 2012; 40: 294–297
DOI: 10.1183/09031936.00187711
CopyrightERS 2012
ERJ Open articles are open access and distributed under the terms of the Creative Commons Attribution Licence 3.0
understanding of the underlying immune phenomena requires
the identification of markers of protection or susceptibility
and the development of laboratory methods and diagnostics
applicable to children [2]. The current lack of suitable diagnostic
reference standards is, however, a barrier for involving children
in research. Deficiencies in suitable diagnostics equally repre-
sent a challenge for the rapid detection and care of children with
TB. New diagnostic methods, including the more sensitive
direct fluorescence sputum microscopy techniques, faster liquid
culture, rapid speciation methods and automated nucleic acid
amplification tests are currently insufficiently evaluated or may
not be suitable for young children, as they rarely produce
sputum and often have paucibacillary disease.
Children were historically excluded from TB drug trials due
to perceived difficulties in case definitions and markers of
treatment response. Their treatment is therefore primarily based
on the adaptation of drug regimens designed for adults. While
there are new World Health Organization (WHO) recommen-
dations for improved childhood TB treatment regimens [3],
there is a lack of child-friendly formulations matching the new
WHO recommendations. Furthermore, the identification and
treatment of children with drug-resistant TB is often based on
limited clinical experience and scarce scientific evidence. The
inclusion of children early in the drug development pathway,
with prioritisation of assessment of their pharmacokinetics,
safety and drug formulation, is critical for the development of
child-friendly and safe treatment regimens.
The Bacille Calmette-Gue´rin (BCG) vaccine protects young
children against severe forms of the disease (e.g. TB meningitis)
and disseminated TB [4, 5]. However, BCG has variable efficacy
against pulmonary TB and severe adverse events in HIV-
infected infants have been reported [6]. BCG vaccination is
therefore recommended to be withheld from infants with
known HIV-positive status while in infants born to HIV-infected
mothers and unknown status, the risks and benefits need to be
considered [7]. Although, the benefits of BCG in most settings
and populations clearly outweigh its risks [7], there is an urgent
need for a more effective and safer TB vaccine for children [8].
Vaccine development would be greatly facilitated by the
identification of immune correlates of protection, the availability
of accurate diagnostic tests for the definition of suitable end-
points for efficacy and the development of additional paediatric
vaccine trial sites.
CHALLENGES AND NEEDS IN PROGRAMMATIC TB
CONTROL FOR CHILDHOOD TB
The basis for establishment of effective childhood TB control is
available and is supported by evidence and best practices. This
includes active case-finding of children in contact with adults
with TB, BCG vaccination, diagnosis of TB, isoniazid preven-
tive therapy to prevent progression of latent TB and treatment
of active disease. Guidelines that focus on the management of
TB in children have been developed in the last 5 yrs, and
provide a framework for NTPs [9]. Despite the fact that these
elements provide the basis for the development of national,
regional and global comprehensive childhood TB control,
broader and systematic implementation has not yet occurred.
Thus, activities to address childhood TB remain fragmented
and are often outside the scope of national and regional
strategies. This creates a policy/practice gap in addressing
control and prevention of TB among children. There is therefore
a need to enhance adoption of international guidelines and to
implement and scale these up within NTPs.
ADVOCACY STRATEGIES IN CHILDHOOD TB
The need for advocacy
The activist movement, which has been key to driving the
global response to HIV/AIDS for over 25 yrs, was non-existent
in TB control until recently [10]. This is particularly true for
childhood TB, which is an indication of failing TB control in
the community [11]. However, childhood TB is often neglected
by scientists, donors, policy makers, healthcare professionals,
product developers and advocates. This is in sharp contrast
with the sense of urgency and innovation that has marked
the response to paediatric HIV. For example, most therapies
approved to treat HIV have paediatric dosing ranges and
child-friendly formulations [12] while there is a dearth of
evidence for the guidelines on TB treatment for children [13]
and a lack of tools to ease treatment of TB in children. Thus,
this vulnerable and neglected population require constant and
effective advocacy on its behalf to address some of the major
challenges (table 1).
Advocacy messages
TB in children is usually not microbiologically confirmed for
a number of well-documented reasons. While concepts fre-
quently used such as ‘‘smear negative’’ or ‘‘paucibacillary’’
may not be difficult to understand for the medical professionals,
they do require explanation as these concepts can complicate
simple messages to the broader community. Childhood TB
advocates need to use language that is accessible and appeals to
a broad audience. Furthermore, messaging should shift from
what is lacking to what is needed and what is possible. While
there is undoubtedly a need for improved diagnostic tools and
therapeutic evidence, especially with second-line drugs, it is
important to recognise that if a diagnosis can be made and a
consistent supply of properly dosed medication is available,
most cases of childhood TB can be cured using current drugs
[14]. Advocacy messages should highlight effective interven-
tions and demand their implementation, and bring focus to gaps
in care and the need for newer and better tools to prevent,
diagnose and treat TB in children of all ages (table 2).
TABLE 1 Major challenges of childhood tuberculosis (TB)
TB is an important cause of child morbidity and mortality, the low priority
awarded to childhood TB due to its lower infectivity is inexcusable
Accurate surveillance data regarding the burden of TB in children are scarce
because it is under-detected and under-reported, this has implications
for the quality of patient care and the recognition and attention awarded
to childhood TB
There is a lack in research and development of improved diagnostic tools,
new drugs, easy-to-dose formulations and effective vaccines to prevent all
forms of TB in children of all ages
Donor interest is lacking and research and programmatic control are under
funded
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Partnerships
TB transmits readily within the household and infants and
young children are at high risk to acquire the infection from
their family members. Specifically, children whose mothers are
co-infected with HIV have an increased risk of TB [15, 16].
Given the family-based nature of the disease, TB services such
as case-finding, preventive therapy and treatment require
better interaction between TB programmes and HIV/AIDS,
immunisation, and child and maternal health programmes.
Thus, TB advocates must collaborate with colleagues from
these other fields to ensure that childhood TB is an integral
part of their practice and policy.
Monitoring and evaluation
TB is a disease of poverty and yet there is no specific mention
of childhood or maternal TB in the Millennium Development
Goals (MDGs), including MDG 4 (reduce child mortality) and
MDG 5 (improve maternal health). Although there are two TB
indicators included in MDG 6 (combat HIV/AIDS, malaria and
other diseases), there is no reference to tracking childhood or
maternal TB.
The US President’s Emergency Plan for AIDS Relief has
included indicators of prevention, diagnosis and treatment of
childhood and maternal TB as essential programme compo-
nents in its guidance to countries [12]. These should be
adopted across global institutions such as the WHO, UN
agencies, and the Global Fund to Fight AIDS, Tuberculosis and
Malaria to establish a uniform framework for monitoring and
evaluating the implementation of childhood and maternal TB
interventions.
A CALL TO ACTION
Childhood TB will remain neglected without strong activism.
Advocates for childhood TB representing a broad spectrum of
public health, research, donors and civil society, and equipped
with the most robust, relevant and up-to-date epidemiological,
clinical and basic science data, must act with a sense of urgency,
outrage and hopefulness. With this in mind, participants at
the International Childhood TB meeting in Stockholm issued a
‘‘Call to Action for Childhood TB’’ [17], the Call to Action can
still be signed via the Stop TB Partnership website [18]. It has
so far been endorsed by over 800 individuals and organisa-
tions from nearly 100 countries. The call urges the international
community to commit to addressing the needs of children at risk
for and suffering from TB.
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